2015-07-30 15:03:12 UTC

AGA Survey Reveals Respondents’ Views on Biosimilar Drugs

July 30, 2015

91 percent of AGA members sampled prescribe biologic drugs for their IBD patients.

As biosimilar drugs are preparing to enter the U.S. market, AGA conducted a member survey to examine current prescribing practices for biologic drugs and explore views on the safety and quality standards needed for biosimilars.

Nearly all of the 180 survey respondents (91 percent) prescribe biologic drugs to their IBD patients, and more than half (60 percent) have had to switch their patient’s treatment due to insurance plans.

Read more about the survey results, which included:

  • More than two-thirds of respondents (81 percent) believe strong evidence of effectiveness is important in determining whether to start a patient on a biologic therapy.
  • Forty percent of respondents felt they were extremely or very familiar with biosimilars, which are therapies similar to, but not exact copies, of innovator biologics.
  • Nearly two-thirds of respondents (72 percent) report that they would be likely to prescribe biosimilars if they became available in the U.S.
  • Sixty-seven percent favored a policy whereby FDA would not allow indication extrapolation in the approval of biosimilars for IBD.

AGA advocates that biosimilar drug names be distinguishable nonproprietary names and that patients should not be forced to switch their biologic treatments without prior notification of their health-care provider.

This survey was conducted by AGA with support from AbbVie. The survey sample has been weighted to match the demographics of AGA’s membership based on region and length of time practicing medicine. The standard margin of error for the survey at the 95 percent confidence level is 7.3 percent. These survey findings do not constitute a formal policy of the AGA and do not necessarily reflect the opinion of the AGA Governing Board members or James Lewis, MD, AGAF.  

For additional information about the use of biologics for the treatment of IBD, review the AGA guideline, Inflammatory Crohn’s Disease: Thiopurines, Methotrexate and Anti-TNF-Alpha Biologic Drugs for Induction and Maintenance of Remission

More on IBD

Advancing Collaborative Approaches in IBD Treatment Decision-Making

March 14, 2018

This is a unique opportunity for payers and providers to gather in the same room to discuss IBD therapy selection, disease monitoring, treatment criteria and access.

Advancing Collaborative Approaches in IBD Treatment Decision-Making

March 12, 2018

This is a unique opportunity for payers and providers to gather in the same room to discuss IBD therapy selection, disease monitoring, treatment criteria and access.

Putting Patients First: Digital Health Tools to Empower IBD Patients

Jan. 18, 2018

Discover how advances in digital health can help you monitor and support IBD patients remotely and dynamically, improve face-to-face care, and drive clinical decisions through shared decision-making.